Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680787 | 0.88 | ALDH1A1 (0.43) | LMNAALDH1A1HTTSMN1; SMN2SLC6A3 | |
| SCHEMBL12194519 | 0.78 | CYP3A4 (0.40) | LMNAALDH1A1HTTSMN1; SMN2SLC6A3 | |
| SCHEMBL681289 | 0.77 | AKT1 (0.38) | SLC6A3SLC6A2SLC6A4CYP3A4 | |
| SCHEMBL16263182 | 0.77 | AKT1 (0.38) | SLC6A3SLC6A2SLC6A4CYP3A4 | |
| SCHEMBL684167 | 0.77 | SLC6A3 (0.47) | LMNAALDH1A1HTTSMN1; SMN2SLC6A3 | |
| SCHEMBL22622609 | 0.76 | CDC7 (0.46) | LMNAALDH1A1HTTSMN1; SMN2SLC6A3 | |
| SCHEMBL22622603 | 0.76 | EPHX2 (0.47) | — | |
| SCHEMBL2738602 | 0.74 | SLC6A3 (0.41) | LMNAALDH1A1HTTSMN1; SMN2SLC6A3 | |
| SCHEMBL680761 | 0.73 | EPHX1 (0.40) | SLC6A3SLC6A4CYP1A2CYP3A4 | |
| SCHEMBL680722 | 0.73 | ALDH1A1 (0.48) | LMNAALDH1A1HTTSMN1; SMN2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | LMNA 3606/4885ALDH1A1 1715/4885HTT 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.